Red Blood Cell Metabolism Modulates Muscle Oxygenation and Limits Exercise Capacity: Insights from a Randomized Double‑Blind Crossover Study
Posted inInternal Medicine news

Red Blood Cell Metabolism Modulates Muscle Oxygenation and Limits Exercise Capacity: Insights from a Randomized Double‑Blind Crossover Study

A randomized crossover study in 20 men shows exercise‑induced oxidative stress alters erythrocyte redox and glycolytic metabolism, reduces 2,3‑BPG/ATP generation, and modestly impairs muscle oxygen extraction and arm exercise VO2peak, suggesting erythrocyte metabolism can influence exercise performance.
Urolithin A in Elite Distance Runners: Improves Recovery and Perceived Effort but Not Race Performance in 4-Week Altitude Training
Posted inInternal Medicine news Public Health

Urolithin A in Elite Distance Runners: Improves Recovery and Perceived Effort but Not Race Performance in 4-Week Altitude Training

A randomized, placebo-controlled trial in highly trained male distance runners found 4 weeks of 1000 mg/day urolithin A reduced markers of muscle damage and perceived exertion and upregulated mitochondrial proteomic pathways, but did not produce statistically significant performance gains in a 3000 m time trial.
Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence
Posted inDiabetes & Endocrinology Internal Medicine news

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, adverse events, cardiovascular outcomes, and evidence certainty.
Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications
Posted inGastroenterology Internal Medicine news

Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications

Non-acute decompensation of cirrhosis (NAD) represents a distinct clinical state characterized by elevated cell death markers and moderate prognosis. Identifying predictors such as ascites severity and biomarkers Gasdermin-D and RIPK3 may guide timely interventions to prevent progression to acute decompensation and reduce mortality.